Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
02 12 2021
02 12 2021
Historique:
received:
18
08
2021
accepted:
15
11
2021
revised:
10
11
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
3
2
2022
Statut:
epublish
Résumé
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
Identifiants
pubmed: 34857730
doi: 10.1038/s41408-021-00587-0
pii: 10.1038/s41408-021-00587-0
pmc: PMC8640034
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
192Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 2016 Jun 20;34(18):2125-32
pubmed: 27114594
Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72
pubmed: 10626149
Am J Hematol. 2014 Feb;89(2):145-50
pubmed: 24123068
Br J Haematol. 2018 Mar;180(6):831-839
pubmed: 29315478
Br J Haematol. 2015 Aug;170(4):523-31
pubmed: 26010293
Leukemia. 2012 Nov;26(11):2398-405
pubmed: 22508408
Clin Cancer Res. 2013 Jun 15;19(12):3130-42
pubmed: 23613318
Arch Intern Med. 1974 May;133(5):813-8
pubmed: 4821776
Blood. 1996 Jul 1;88(1):289-96
pubmed: 8704185
Haematologica. 2017 Jun;102(6):1099-1104
pubmed: 28255016
Blood. 1999 Feb 1;93(3):1032-7
pubmed: 9920853
Haematologica. 2010 May;95(5):804-9
pubmed: 20442444
Leuk Res. 2018 Oct;73:95-102
pubmed: 30257227
Leukemia. 2014 Jan;28(1):222-5
pubmed: 23958922
Leukemia. 2008 May;22(5):1044-52
pubmed: 18216867
Ann Hematol. 2015 Feb;94(2):257-64
pubmed: 25231928
Blood Cancer J. 2018 Nov 19;8(12):117
pubmed: 30455467
Blood. 2005 Oct 1;106(7):2276-9
pubmed: 15961515
Leukemia. 2014 Oct;28(10):2060-5
pubmed: 24618735
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Leukemia. 2013 Apr;27(4):780-91
pubmed: 23288300
Leuk Lymphoma. 2007 Jan;48(1):207-8
pubmed: 17325872
Br J Haematol. 1994 Dec;88(4):754-9
pubmed: 7819100
Leukemia. 2017 Jan;31(1):130-135
pubmed: 27457702
Cancer. 2019 Feb 1;125(3):416-423
pubmed: 30332496
Leukemia. 2012 May;26(5):1091-7
pubmed: 22042147
Blood. 2012 Sep 20;120(12):2376-89
pubmed: 22837533
Leuk Lymphoma. 2003 Feb;44(2):379-80
pubmed: 12688365
Blood. 2014 Aug 7;124(6):907-12
pubmed: 24957143
Ann Oncol. 2012 Jun;23(6):1499-502
pubmed: 22039089
Blood Cancer J. 2018 Nov 15;8(12):116
pubmed: 30442928
Am J Med. 1987 Dec;83(6):1062-8
pubmed: 3503574